Puma Biotechnology Inc. (PBYI) Insider Trading

Last 12 months

Insiders sold $2.12M and bought nothing on the open market.

95% of the selling was scheduled in advance under 10b5-1 plans. Director Michael Patrick Miller sold $97k on Nov 11, 2025, 27% of their stake, outside a plan. The last open-market buy by an executive or director was in Apr 2014.

Net open-market

−$2.12M

0 buys · 14 sales

Under a 10b5-1 plan

95%

of the value sold

Insiders who bought / sold

0 / 10

executives and directors

Last open-market buy

Apr 2014

Apr 11, 2014

Get an email when PBYI's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

Date	Insider	Trade	Shares	Price	Value	Of their stake	Filing
Sep 14	Troy Edward Wilson Director	Sold10b5-1 plan	5,000	$9.10	$46k	8.3%	Form 4
Sep 14	Alessandra Cesano Director	Sold10b5-1 plan	62,150	$9.12	$567k	52%	Form 4
Jul 6	Alan H Auerbach President and CEO	Sold10b5-1 plan	44,058	$8.26	$364k	0.6%	Form 4
Jul 6	Douglas M Hunt See Remarks	Sold10b5-1 plan	8,460	$8.26	$70k	4.1%	Form 4
Jul 6	Maximo F Nougues Chief Financial Officer	Sold10b5-1 plan	9,386	$8.26	$78k	3.9%	Form 4
Jun 12	Troy Edward Wilson Director	Sold10b5-1 plan	10,800	$7.20	$78k	15%	Form 4
Jun 12	Brian M Stuglik Director	Sold10b5-1 plan	8,100	$7.20	$58k	6.6%	Form 4
Jun 12	Adrian Senderowicz Director	Sold10b5-1 plan	27,000	$7.20	$194k	50%	Form 4
Jun 12	Jay M Moyes Director	Sold10b5-1 plan	22,000	$7.22	$159k	27%	Form 4
Jun 12	Allison Dorval Director	Sold10b5-1 plan	11,610	$7.20	$84k	11%	Form 4
Jan 6 – 7	Alan H Auerbach President and CEO	Sold10b5-1 plan 2 parts	34,950	$5.86 average	$205k	0.5%	Form 4
Jan 6 – 7	Douglas M Hunt See Remarks	Sold10b5-1 plan 2 parts	8,987	$5.86 average	$53k	5.5%	Form 4
Jan 6 – 7	Maximo F Nougues Chief Financial Officer	Sold10b5-1 plan 2 parts	10,945	$5.86 average	$64k	5.4%	Form 4
Nov 11, 2025	Michael Patrick Miller Director	SoldNo plan	20,000	$4.86	$97k	27%	Form 4
Jul 18, 2025	Alessandra Cesano Director	Sold10b5-1 plan	27,000	$3.37	$91k	39%	Form 4
Jul 8, 2025 – Jul 9, 2025	Maximo F Nougues Chief Financial Officer	Sold10b5-1 plan 2 parts	9,522	$3.53 average	$34k	4.5%	Form 4
Jul 8, 2025 – Jul 9, 2025	Douglas M Hunt See Remarks	Sold10b5-1 plan 2 parts	7,817	$3.53 average	$28k	4.5%	Form 4
Jul 8, 2025 – Jul 9, 2025	Alan H Auerbach President and CEO	Sold10b5-1 plan 2 parts	47,172	$3.53 average	$167k	0.7%	Form 4
Jun 13, 2025	Troy Edward Wilson Director	Sold10b5-1 plan	10,800	$3.40	$37k	20%	Form 4
Jun 13, 2025	Brian M Stuglik Director	Sold10b5-1 plan	8,100	$3.39	$27k	7.9%	Form 4
Jun 13, 2025	Adrian Senderowicz Director	Sold10b5-1 plan	27,000	$3.40	$92k	50%	Form 4
Jun 13, 2025	Jay M Moyes Director	Sold10b5-1 plan	22,000	$3.40	$75k	29%	Form 4
Jun 13, 2025	Allison Dorval Director	Sold10b5-1 plan	11,610	$3.40	$39k	13%	Form 4
Jun 13, 2025	Alessandra Cesano Director	Sold10b5-1 plan	12,150	$3.40	$41k	15%	Form 4
Jan 2, 2025	Maximo F Nougues Chief Financial Officer	Sold10b5-1 plan	10,227	$3.15	$32k	6.3%	Form 4
Jan 2, 2025	Jeffrey Jerome Ludwig Chief Commercial Officer	Sold10b5-1 plan	9,437	$3.15	$30k	8.0%	Form 4
Jan 2, 2025	Douglas M Hunt See Remarks	Sold10b5-1 plan	8,633	$3.15	$27k	6.5%	Form 4
Jan 2, 2025	Alan H Auerbach President and CEO	Sold10b5-1 plan	33,841	$3.15	$107k	0.5%	Form 4

Sep 1410b5-1 plan
Troy Edward Wilson
Director · sold 5,000 at $9.10
$46k
8.3% of stake
Sep 1410b5-1 plan
Alessandra Cesano
Director · sold 62,150 at $9.12
$567k
52% of stake
Jul 610b5-1 plan
Alan H Auerbach
President and CEO · sold 44,058 at $8.26
$364k
0.6% of stake
Jul 610b5-1 plan
Douglas M Hunt
See Remarks · sold 8,460 at $8.26
$70k
4.1% of stake
Jul 610b5-1 plan
Maximo F Nougues
Chief Financial Officer · sold 9,386 at $8.26
$78k
3.9% of stake
Jun 1210b5-1 plan
Troy Edward Wilson
Director · sold 10,800 at $7.20
$78k
15% of stake
Jun 1210b5-1 plan
Brian M Stuglik
Director · sold 8,100 at $7.20
$58k
6.6% of stake
Jun 1210b5-1 plan
Adrian Senderowicz
Director · sold 27,000 at $7.20
$194k
50% of stake
Jun 1210b5-1 plan
Jay M Moyes
Director · sold 22,000 at $7.22
$159k
27% of stake
Jun 1210b5-1 plan
Allison Dorval
Director · sold 11,610 at $7.20
$84k
11% of stake
Jan 6 – 710b5-1 plan
Alan H Auerbach
President and CEO · sold 34,950 at avg $5.86
$205k
0.5% of stake
Jan 6 – 710b5-1 plan
Douglas M Hunt
See Remarks · sold 8,987 at avg $5.86
$53k
5.5% of stake
Jan 6 – 710b5-1 plan
Maximo F Nougues
Chief Financial Officer · sold 10,945 at avg $5.86
$64k
5.4% of stake
Nov 11, 2025No plan
Michael Patrick Miller
Director · sold 20,000 at $4.86
$97k
27% of stake
Jul 18, 202510b5-1 plan
Alessandra Cesano
Director · sold 27,000 at $3.37
$91k
39% of stake
Jul 8, 2025 – Jul 9, 202510b5-1 plan
Maximo F Nougues
Chief Financial Officer · sold 9,522 at avg $3.53
$34k
4.5% of stake
Jul 8, 2025 – Jul 9, 202510b5-1 plan
Douglas M Hunt
See Remarks · sold 7,817 at avg $3.53
$28k
4.5% of stake
Jul 8, 2025 – Jul 9, 202510b5-1 plan
Alan H Auerbach
President and CEO · sold 47,172 at avg $3.53
$167k
0.7% of stake
Jun 13, 202510b5-1 plan
Troy Edward Wilson
Director · sold 10,800 at $3.40
$37k
20% of stake
Jun 13, 202510b5-1 plan
Brian M Stuglik
Director · sold 8,100 at $3.39
$27k
7.9% of stake
Jun 13, 202510b5-1 plan
Adrian Senderowicz
Director · sold 27,000 at $3.40
$92k
50% of stake
Jun 13, 202510b5-1 plan
Jay M Moyes
Director · sold 22,000 at $3.40
$75k
29% of stake
Jun 13, 202510b5-1 plan
Allison Dorval
Director · sold 11,610 at $3.40
$39k
13% of stake
Jun 13, 202510b5-1 plan
Alessandra Cesano
Director · sold 12,150 at $3.40
$41k
15% of stake
Jan 2, 202510b5-1 plan
Maximo F Nougues
Chief Financial Officer · sold 10,227 at $3.15
$32k
6.3% of stake
Jan 2, 202510b5-1 plan
Jeffrey Jerome Ludwig
Chief Commercial Officer · sold 9,437 at $3.15
$30k
8.0% of stake
Jan 2, 202510b5-1 plan
Douglas M Hunt
See Remarks · sold 8,633 at $3.15
$27k
6.5% of stake
Jan 2, 202510b5-1 plan
Alan H Auerbach
President and CEO · sold 33,841 at $3.15
$107k
0.5% of stake

How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch PBYI, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Related stocks: Pharmaceutical Preparations

ANABAnaptysBio Inc.

RCUSArcus Biosciences Inc.

PHATPhathom Pharmaceuticals Inc.

RYTMRhythm Pharmaceuticals Inc.

AKBAAkebia Therapeutics Inc.

IDYAIdeaya Biosciences Inc.

VNDAVanda Pharmaceuticals Inc.

SNDXSyndax Pharmaceuticals Inc.

Spot a number that looks wrong? Check it in PBYI's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing PBYI

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.